MDM2 and breast cancer: In BC models, the targeted inhibition of MDM2, an E3-ubiquitin-ligase, has shown promising therapeutic effects either through its autoubiquitination and proteasomal degradation by SP-141 or by blocking the p53-MDM2 interaction by WK298 and SJ-172550 [17,18].